The Clorox Company (NYSE:CLX) Receives Average Recommendation of "Reduce" from Analysts

Key Points

• The Clorox Company has received an average analyst recommendation of "Reduce," with three analysts suggesting a sell, ten a hold, and one a buy, while the average 12-month price target is approximately $134.08.
• Recent price target adjustments include TD Cowen lowering it from $120 to $117 with a "hold" rating, while other firms have similarly decreased targets and maintained neutral or sell ratings.
• Clorox declared a quarterly dividend of $1.24 per share payable on November 6th, representing an annualized yield of 4.0%, while the stock currently trades at around $123.30.

Shares of The Clorox Company (NYSE:CLX - Get Free Report) have received an average recommendation of "Reduce" from the fourteen analysts that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $134.0833.

CLX has been the topic of several recent analyst reports. TD Cowen dropped their target price on Clorox from $120.00 to $117.00 and set a "hold" rating on the stock in a research report on Wednesday. The Goldman Sachs Group decreased their price target on Clorox from $115.00 to $110.00 and set a "sell" rating on the stock in a research note on Wednesday. Jefferies Financial Group cut their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. JPMorgan Chase & Co. raised their target price on Clorox from $133.00 to $135.00 and gave the company a "neutral" rating in a report on Monday, September 8th. Finally, Citigroup reaffirmed a "neutral" rating and set a $135.00 price target (down from $140.00) on shares of Clorox in a research note on Tuesday, July 15th.

Clorox Stock Performance

Shares of CLX opened at $123.30 on Friday. The stock has a market capitalization of $15.08 billion, a P/E ratio of 18.91, a P/E/G ratio of 0.98 and a beta of 0.52. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. Clorox has a 1 year low of $116.53 and a 1 year high of $171.37. The company's fifty day moving average is $122.81 and its two-hundred day moving average is $129.64.

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The business had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the previous year, the firm earned $1.82 earnings per share. The business's quarterly revenue was up 4.5% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. On average, sell-side analysts predict that Clorox will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Stockholders of record on Wednesday, October 22nd will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date is Wednesday, October 22nd. Clorox's dividend payout ratio (DPR) is presently 76.07%.

Insider Activity at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer owned 54,221 shares in the company, valued at $6,711,475.38. This represents a 21.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.57% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Invesco Ltd. raised its position in shares of Clorox by 138.3% during the 2nd quarter. Invesco Ltd. now owns 3,245,175 shares of the company's stock worth $389,648,000 after purchasing an additional 1,883,465 shares during the last quarter. Norges Bank purchased a new position in Clorox during the second quarter worth $190,429,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Clorox by 218.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company's stock worth $149,983,000 after acquiring an additional 856,873 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in shares of Clorox in the second quarter valued at $71,856,000. Finally, Hsbc Holdings PLC boosted its stake in shares of Clorox by 118.8% during the first quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company's stock valued at $159,699,000 after acquiring an additional 589,544 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.